Kevin Winders, MD
Child & Adolescent Psychiatry · Savannah, GANPI 1275577520
Payments from drug & device makers
Across 750 payments — averaging $300.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$185K
- Supernus Pharmaceuticals, Inc.$25K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Corium, LLC$557
- Teva Pharmaceuticals USA, Inc.$468
- Ironshore Pharmaceuticals Inc.$449
- plus $4K from 23 others
What the payments were for
- Speaking & faculty fees$208,91593%
- Travel & lodging$6,5703%
- Food & beverage$9,8344%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 306 | $185,443 |
| Supernus Pharmaceuticals, Inc. | 126 | $24,858 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $9,878 |
| Corium, LLC | 19 | $557 |
| Teva Pharmaceuticals USA, Inc. | 12 | $468 |
| Ironshore Pharmaceuticals Inc. | 21 | $449 |
| Johnson & Johnson | 27 | $436 |
| Sunovion Pharmaceuticals Inc. | 22 | $386 |
| Adlon Therapeutics L.p. | 23 | $349 |
| Neos Therapeutics, LP | 29 | $315 |
| Bausch Health US, LLC | 14 | $314 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $310 |
| Tris Pharma Inc | 15 | $304 |
| Otsuka America Pharmaceutical, Inc. | 13 | $246 |
| Lundbeck LLC | 11 | $207 |
| Jazz Pharmaceuticals Inc. | 8 | $161 |
| Eisai Inc. | 7 | $102 |
| Shire North American Group Inc | 7 | $101 |
| Alkermes, Inc. | 5 | $94 |
| Axsome Therapeutics, Inc. | 3 | $84 |
| Vanda Pharmaceuticals Inc. | 3 | $77 |
| Neurocrine Biosciences, Inc. | 4 | $62 |
| Arbor Pharmaceuticals, Inc. | 4 | $59 |
| Harmony Biosciences LLC | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $13 |
| Neuronetics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$178,370
- QELBREE$18,230
- TRINTELLIX$8,922
- Azstarys$280
- UZEDY$128
- Austedo XR$125
- JORNAY PM$115
How this compares
$225,384 in reported general payments places this provider in the 95th percentile of 91 child & adolescent psychiatry providers in Georgia.
See all child & adolescent psychiatry providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 47 | $32,197 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $6,911 |
| Adderall XrDextroamphetamine/Amphetamine | 11 | $6,632 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 36 | $5,951 |
| Lisdexamfetamine Dimesylate | 14 | $3,565 |
| Bupropion XlBupropion Hcl | 92 | $3,072 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 52 | $2,536 |
| Vilazodone Hcl | 11 | $1,626 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 62 | $1,530 |
| Escitalopram Oxalate | 103 | $1,152 |
| Duloxetine Hcl | 38 | $953 |
| Carbamazepine ErCarbamazepine | 12 | $860 |
| Trazodone Hcl | 57 | $690 |
| Buspirone Hcl | 52 | $618 |
| Quetiapine Fumarate | 55 | $618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $9,878 | $39,10763 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 91 child & adolescent psychiatry providers in Georgia.
Other child & adolescent psychiatry in Savannah
- Suneel KatragaddaAtlanta$2.1M
- Olufemi TaiwoFayetteville$173K
- Annamarie PaulsenConyers$25K
- Haolat BabalakinBerkeley Lake$16K
- Heerain ShahSuwanee$14K
- Olujimi AdefisanAtlanta$14K
- Deepti BhasinWarner Robins$11K
- Mhd AlkhatibAtlanta$7K
- Mary HuberAtlanta$7K
- Jocelyn BaylissAugusta$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.